Get the Stockscreener App
132.26
1.49%
1.94
After Hours:
133.04
0.78
+0.59%
Illumina Inc stock is traded at $132.26, with a volume of 1.46M.
It is up +1.49% in the last 24 hours and up +11.20% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$130.32
Open:
$130.34
24h Volume:
1.46M
Relative Volume:
0.75
Market Cap:
$20.09B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
24.21
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
+3.33%
1M Performance:
+11.20%
6M Performance:
+42.22%
1Y Performance:
+77.32%
1-Day Range:
$130.20
$133.37
1-Week Range:
$118.30
$133.37
52-Week Range:
$69.83
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
132.26 | 19.80B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
531.67 | 195.93B | 44.56B | 6.72B | 6.29B | 17.74 |
DHR
Danaher Corp
|
198.14 | 140.56B | 24.57B | 3.60B | 5.26B | 5.051 |
IDXX
Idexx Laboratories Inc
|
580.76 | 46.39B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
119.77 | 34.02B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
326.20 | 32.49B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina Inc. stock (US4523271090): Why does its genomics dominance matter more now for U.S. investo - AD HOC NEWS
Illumina’s Pediatric Genomics Push Tests Long Term Growth Narrative - Yahoo Finance
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
How Investors Are Reacting To Illumina (ILMN) Board Turnover And Expanded Labcorp Precision Oncology Partnership - simplywall.st
Illumina partners with D3b on pediatric genomic data initiative - Investing.com
Illumina Partners with D3b to Advance Pediatric Cancer Research - Intellectia AI
100,000 child genomes power rare disease and cancer research - Stock Titan
Third View Private Wealth LLC Buys Shares of Illumina, Inc. - National Today
Administrator Loeffler Applauds SBIR-STTR Reauthorization - GlobeNewswire Inc.
Hardman Johnston Trims Illumina Stake - National Today
Bioinformatics Market 2026- 2033 Overview: Share, Size, Value, - openPR.com
Illumina (ILMN), Labcorp (LH) Expand Precision Oncology NGS Collaboration - Insider Monkey
Epigenetics Market to Grow from US$ 2.06 Billion in 2024 to US$ - openPR.com
Illumina Inc. stock (US4523271090): Is its genomics leadership strong enough for long-term U.S. inve - AD HOC NEWS
Is It Time To Reassess Illumina (ILMN) After Its 61.7% One Year Share Price Rebound - Yahoo Finance
Is Illumina Stock Undervalued at $121? - TIKR.com
Illumina Inc stock (US4523271090): Is its genomics dominance strong enough to unlock new upside? - AD HOC NEWS
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - GlobeNewswire Inc.
Illumina Stock: Competitive Threats Priced In (NASDAQ:ILMN) - Seeking Alpha
Illumina Inc (ILMN) Stock Down 3.4% -- Now Undervalued? GF Score: 83/100 - GuruFocus
Informatics advances reveal the TruPath™ Genome towards comprehensive genomic insights - Illumina
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026 - marketscreener.com
Illumina Inc. stock rises Wednesday, still underperforms market - MarketWatch
(ILMN) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Illumina, Inc. (ILMN) Stock Forecasts - Yahoo Finance
New Zealand gains genomic testing independence - Illumina
Illumina, Inc. $ILMN Shares Sold by Aberdeen Group plc - MarketBeat
The Evolving Landscape of Proteomics: HUPO World Congress Interview with Professor Stuart Cordwell - Illumina
Illumina rejigs board of directors - Medical Buyer
Cathie Wood's Called It Years Ago – Illumina Is the Must-Own Personalized Biotech Stock - Money Morning
Illumina, Inc. (ILMN) stock price, news, quote and history - Yahoo Finance Singapore
Illumina Inc (ILU.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina, Inc. (ILMN) Stock Price, News, Quote & History - Yahoo! Finance Canada
Illumina Stock Hits Day Low of $116.75 Amid Price Pressure - Markets Mojo
Cancer Biopsy Market Set to Boom Rapidly, Witnessing Strong - openPR.com
Liquid Biopsy Products Market Is Going to Boom | Illumina • Biocept • Natera • Roche - openPR.com
Illumina, Inc. (ILMN) latest stock news and headlines - Yahoo Finance Singapore
Illumina adds King to board as three directors retire By Investing.com - Investing.com Australia
Illumina Announces Changes to Board of Directors - The Malaysian Reserve
Illumina (ILMN) director Scott Ullem takes 2026 retainer as 190 ILMN shares - Stock Titan
Illumina (NASDAQ: ILMN) director paid in stock, linked to Corvex funds - Stock Titan
Illumina's 'Obvious Mistake' Not Enough To Chuck UPC Claim - Law360
UPC refuses early knockout in Illumina–Element dispute - Life Sciences Intellectual Property Review
Illumina, Inc. Announces Board Retirements, Effective May 21, 2026 - marketscreener.com
Illumina adds King to board as three directors retire - Investing.com
Illumina Announces Board Retirements and New Director Nominee - TipRanks
Illumina (NASDAQ: ILMN) nominates David P. King as three directors retire - Stock Titan
AAV Genome Sequencing Service Market Is Booming Rapidly with - openPR.com
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.41%
1.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):